Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults - Wikidata - awgldk - TriplyDB

Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults

Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults

http://www.wikidata.org/entity/Q34699094

about

Influenza vaccination in HIV-positive subjects: latest evidence and future perspective Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients Seroconversion of 2009 pandemic influenza A (H1N1) vaccination in kidney transplant patients and the influence of different risk factors.Immune activation and viral replication after vaccination with an influenza A H1N1 2009 vaccine in HIV-infected children receiving antiretroviral therapy.Immunogenicity of Licensed Influenza A (H1N1) 2009 Monovalent Vaccines in HIV-Infected Children and Youth.Influenza vaccination in immunocompromised patients: efficacy and safety.High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine.Durability of protective antibody titres is not enhanced by a two-dose schedule of an ASO3-adjuvanted pandemic H1N1 influenza vaccine in adult HIV-1-infected patients.Low expression of activation marker CD69 and chemokine receptors CCR5 and CXCR3 on memory T cells after 2009 H1N1 influenza A antigen stimulation in vitro following H1N1 vaccination of HIV-infected individuals Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults.Pandemic influenza vaccination elicits influenza-specific CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports.Influenza and HIV: lessons from the 2009 H1N1 influenza pandemic.Unadjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected adults.High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults.Cellular and humoral immune responses to pandemic influenza vaccine in healthy and in highly active antiretroviral therapy-treated HIV patients.Decreased serologic response in vaccinated military recruits during 2011 correspond to genetic drift in concurrent circulating pandemic A/H1N1 viruses.Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults.Immunogenicity and tolerability after two doses of non-adjuvanted, whole-virion pandemic influenza A (H1N1) vaccine in HIV-infected individuals.H1N1pdm09 adjuvanted vaccination in HIV-infected adults: a randomized trial of two single versus two double doses.Immune response to 2009 H1N1 vaccine in HIV-infected adults in Northern Thailand.High proportions of regulatory B and T cells are associated with decreased cellular responses to pH1N1 influenza vaccine in HIV-infected children and youth (IMPAACT P1088)Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women.Naturally-acquired influenza-specific CD4+ T-cell proliferative responses are impaired in HIV-infected African adults.Vaccination in HIV-infected adults.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.Comparative analysis of hemagglutination inhibition titers generated using temporally matched serum and plasma samples.Representation of women and pregnant women in HIV research: a limited systematic review.Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults.Kinetics of Hemagglutination-Inhibiting Antibodies Following Maternal Influenza Vaccination Among Mothers With and Those Without HIV Infection and Their Infants Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand.Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults.Association of CMV, HBV, or HCV co-infection with vaccine response in adults with well-controlled HIV infection Safety and immunogenicity of influenza vaccine among HIV-infected adults: Conventional vaccine vs. intradermal vaccine Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controls.Vaccinations for the HIV-Infected Adult: A Review of the Current Recommendations, Part I.Fluzone® High-Dose Influenza Vaccine.Vaccination of HIV-infected pregnant women: implications for protection of their young infants.British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015.

P2860

Q27007483-AFC4193D-8D95-447B-B800-E73230A4148D Q28743021-3AF9C8B3-08F4-426A-99B1-E8FA040B3320 Q30354634-634E391B-85DA-496E-AD96-8CED38C744F8 Q30354991-88983669-1F13-41B8-A5E1-6F20C39DDAAA Q30357158-A50640EA-37EF-4F13-96E4-DAFD5723F7FF Q30358640-3236D93A-FD67-4054-A286-E7684726D948 Q30362521-EF14BD2E-AA09-4136-8040-9FBDD2FCDD48 Q30364472-74CCA376-5ECD-4D21-AC3A-D972276598A3 Q30375875-95BA04EE-B490-4CA7-BFB8-599AE0B2FBC9 Q30400385-94DEE478-B219-48DB-8FC4-B7065F4E4D5C Q30401158-8AFB4727-A483-4788-B208-FA0A860E7ED0 Q30404293-4379D923-673F-4FA4-BED3-3734361B5F22 Q30407911-42DE599F-2AD2-4D70-9499-E370412C453E Q30412595-D62F66FA-40D8-4FE5-A7E9-1920F878CD76 Q30414543-8CB45799-2507-4852-9B6A-5E6F59614883 Q30415565-804725AE-4B30-490E-9CB3-79E68B66BA21 Q30417077-F41296FC-3316-46E1-BF31-A75452CD354F Q30417245-48B05934-B3AF-4B6B-9FBE-42D9D07635B7 Q30418834-89F2FE21-A775-447E-A3AA-F62B8DAB858F Q30420476-A800EF09-31E4-4CAE-858F-803ADF9F7D0B Q30426654-0DF6287C-CCD1-4E0C-8486-FD71285A42AC Q30426754-DFEB40EB-7453-4308-A139-26B7CDB2DD43 Q31065881-3CB88D1C-B9C1-474F-9078-2CA2090540F3 Q33980764-A237BFD0-B17E-4D63-A7F7-AC8A6A92C2FF Q34212799-845A13B5-D015-425B-A2D2-BC25C3586B13 Q34390072-2B9651BA-E5E4-43B8-9859-C2CD16B33712 Q34531413-76FDD045-D21E-4DB3-8F32-5D8541C2DD6C Q34979789-ACCB5873-AA59-48E5-B1AE-0B70BDD379EF Q35741958-7FCD5DD2-2C5E-4A1E-9542-D04AF5AD4A4C Q35965234-BF610614-B7A4-4041-BC86-8330440D0FE9 Q36306940-FC9CE450-09C6-4D21-A088-FAD94A7A94A7 Q36447589-ADEBFFF9-4ADD-4FD1-AB7B-CAAC31611CCA Q36552868-95477CB2-CF48-4328-8B76-4F28991941B8 Q37131078-2F8154B2-584F-424A-8F76-6D2518D2EB76 Q37309289-483D6BD7-A102-46A8-89AA-E4D24CEF4762 Q38446730-D3102F14-619C-4F82-971B-63E0D382336A Q38639401-59CB9E8F-7551-4047-A3AB-428FA0455545 Q38998621-3AE79C4D-C9F2-42E7-9011-D9E4620C931B Q40051928-0C191F2B-052C-4D34-9E5A-2B6BED37D4A6 Q40560650-C8387F53-84D5-4D05-9ECF-7BE3D1BB0930

P2860

Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults

http://www.wikidata.org/entity/Q34699094

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Immunogenicity of a monovalent ...... lts with HIV-uninfected adults

@ast

Immunogenicity of a monovalent ...... lts with HIV-uninfected adults

@en

type

label

Immunogenicity of a monovalent ...... lts with HIV-uninfected adults

@ast

Immunogenicity of a monovalent ...... lts with HIV-uninfected adults

@en

prefLabel

Immunogenicity of a monovalent ...... lts with HIV-uninfected adults

@ast

Immunogenicity of a monovalent ...... lts with HIV-uninfected adults

@en

P1433

Q34699094-D381100D-43BD-4315-9DCD-7674D246E509

P1476

Q34699094-419A9970-4004-4273-8A3A-44D3A375BEC9

P2093

Q34699094-0AD0D74E-B0E4-4657-ACAD-0DBD473AB968

Q34699094-6F3E8A11-5D3B-4FE0-B3A7-4C34C2A6543E

Q34699094-76D0454F-E421-4DC2-B931-9805BDBF7851

Q34699094-8D893B25-CFA5-4D8F-A599-322B06E95310

Q34699094-A6A8BF95-5A69-40A9-A79F-107DCE519833

Q34699094-A768A30A-D711-40BE-8B86-918242A7A726

Q34699094-A8FF54A4-DBCF-4B78-9B07-024E16105909

Q34699094-B54204D8-16B3-4287-97F4-26033FD92B14

Q34699094-B762F2F9-CA9D-4321-B018-B510D90C8A84

Q34699094-C64BED5C-BEB3-4FFB-96F1-28D64B95E50A

P2860

Q34699094-017041F2-8EED-4256-B7AF-6D64CA4FAFF0

Q34699094-04A8CB65-0E64-4604-9335-F518DFA2433E

Q34699094-07DABC1E-CB2A-46B6-863B-DA7C97BAA882

Q34699094-0F61CAA8-D5D3-4748-BA49-C178EA2A99A2

Q34699094-1138C282-4AA7-434E-A76B-3869B4D1146A

Q34699094-1A81D3FB-FA62-4CA2-B1C6-0935044E3DCB

Q34699094-2A2B255C-2409-4EA9-AC3F-27AE054F6090

Q34699094-34155F42-A8EB-4749-BF01-D5F3445969AA

Q34699094-3C6A9FC1-AD7A-4AFC-B8FE-1893BE54C009

Q34699094-4620FDA8-FBC5-452B-8F83-B62BFF3F50FC

P304

Q34699094-B28EF0F3-D8E9-4CF6-A727-E58B6DF6CAB4

P31

Q34699094-553260B3-E854-4656-94BE-E8B5B92F086B

P356

Q34699094-784C64A1-0015-4BC7-82BA-EB6F9F2D0C87

P407

Q34699094-A4360D05-715E-4B4E-B6C1-A7E05B24CF93

P433

Q34699094-2A62AD61-930C-40A7-B209-0F89F76EE987

P478

Q34699094-55E87999-8925-4066-9631-D1676588C46C

P50

Q34699094-65817601-F9FA-4686-9459-2806C310FC8B

Q34699094-9F804566-9D6F-4C79-A323-2C9FF56DB91D

P577

Q34699094-84ECF750-AFAD-4D68-98B6-CB22F39D376F

P5875

Q34699094-028BA339-DFA8-4E68-B131-3007A65773FA

P698

Q34699094-1C7B9F39-933F-466A-8CE0-2E9CE03F0B54

P932

Q34699094-C6BCB7B5-F752-4791-B256-5E984585AF95

P356

P1433

Clinical Infectious Diseases

P1476

Immunogenicity of a monovalent ...... lts with HIV-uninfected adults

@en

P2093

Carolyn Brandt

http://www.w3.org/2001/XMLSchema#string

Chris Duplessis

http://www.w3.org/2001/XMLSchema#string

Dennis Faix

http://www.w3.org/2001/XMLSchema#string

Erik Iverson

http://www.w3.org/2001/XMLSchema#string

Gabriel Defang

http://www.w3.org/2001/XMLSchema#string

Grace Macalino

http://www.w3.org/2001/XMLSchema#string

Jason Maguire

http://www.w3.org/2001/XMLSchema#string

Nancy F Crum-Cianflone

http://www.w3.org/2001/XMLSchema#string

Patrick J Blair

http://www.w3.org/2001/XMLSchema#string

Tahaniyat Lalani

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of the efficacy and cross-protectivity of recent human and swine vaccines against the pandemic (H1N1) 2009 virus infection

Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis.

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

Response to a monovalent 2009 influenza A (H1N1) vaccine.

A novel influenza A (H1N1) vaccine in various age groups.

Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.

Comparison of the effects of acute influenza infection and Influenza vaccination on HIV viral load and CD4 cell counts.

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.

P304

138-146

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIQ019

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

Anuradha Ganesan

P577

2010-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49674398

http://www.w3.org/2001/XMLSchema#string

P698

21148532

http://www.w3.org/2001/XMLSchema#string

P932

3060889

http://www.w3.org/2001/XMLSchema#string